NCT00193193View on ClinicalTrials.gov

Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 31, 2000

Primary Completion Date

December 31, 2003

Study Completion Date

February 28, 2007

Conditions

Prostate Cancer

Interventions

DRUG

Paclitaxel

DRUG

Estramustine

DRUG

Carboplatin

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT00193193 - Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma | Biotech Hunter | Biotech Hunter